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a b s t r a c t
The influenza A/H1N1 pandemic in 2009 taught us that the monitoring of vaccine benefits and risks in
Europe had potential for improvement if different public and private stakeholders would collaborate bet-
ter (public health institutes (PHIs), regulatory authorities, research institutes, vaccine manufacturers).
The Innovative Medicines Initiative (IMI) subsequently issued a competitive call to establish a public-
private partnership to build and test a novel system for monitoring vaccine benefits and risks in
Europe. The ADVANCE project (Accelerated Development of Vaccine benefit-risk Collaboration in
Europe) was created as a result. The objective of this paper is to describe the perspectives of key stake-
holder groups of the ADVANCE consortium for vaccine benefit-risk monitoring and their views on how to
build a European system addressing the needs and challenges of such monitoring. These perspectives and
needs were assessed at the start of the ADVANCE project by the European Medicines Agency together
with representatives of the main stakeholders in the field of vaccines within and outside the ADVANCE
consortium (i.e. research institutes, public health institutes, medicines regulatory authorities, vaccine
manufacturers, patient associations). Although all stakeholder representatives stated they conduct vac-
cine benefit-risk monitoring according to their own remit, needs and obligations, they are faced with sim-
ilar challenges and needs for improved collaboration. A robust, rapid system yielding high-quality
information on the benefits and risks of vaccines would therefore support their decision making.
https://doi.org/10.1016/j.vaccine.2019.07.081
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ADVANCE has developed such a system and has tested its performance in a series of proof of concept
(POC) studies. The system, how it was used and the results from the POC studies are described in the
papers in this supplementary issue.
 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
1.1. Vaccines are needed
Immunisation has a major impact on global health [1]. Today,
vaccines are licensed for protection against more than 20 diseases
(Fig. 1) and are now one of the most successful and cost-effective
medical interventions to protect billions of people [2,3]. Immunisa-
tion is estimated to prevent 2–3 million deaths annually across all
age groups [4]. High vaccination coverage in a population and sub-
sequent herd immunity can protect those who cannot be vacci-
nated. Additionally, advancements in maternal immunisation
have led to protection of new-borns against vaccine-preventable
diseases, such as tetanus, pertussis and influenza. Over the next
decade, the world’s population can also expect to benefit from vac-
cines for diseases and pathogens such as HIV/AIDS and Group B
Streptococcus [5]. In the future, vaccines may play a more promi-
nent role in the fight against antimicrobial resistance, one of the
largest public health threats. In the European Union (EU), vaccine
products are licensed through the European Medicines Agency
(EMA) or a national regulatory authority, and are subsequently
monitored by the regulatory authorities; vaccination programmes
are monitored by public health institutes (PHIs) [6]. Vaccine man-
ufacturers have their own legal responsibility for monitoring
product-specific benefit-risk.
1.2. Vaccination hesitancy is concerning
Despite the well-documented benefits of vaccination, some
population groups in a number of European countries are hesitant
about vaccination, reporting mistrust in vaccine safety and ques-
tioning the trustworthiness of government, regulatory and public
health authorities and pharmaceutical companies [7]. Hesitancy
has been partly fuelled by the Wakefield publication that claimed
autism was caused by MMR vaccine, which was later identified
as fraudulent research and retracted 12 years after its publication
[8]. Vaccination programmes are also victims of their own success,
as some vaccine-preventable diseases are now so rare that the ben-
efits of vaccination are less obvious to the public, who are more
concerned about vaccine risks than disease risks, as well as by
the increasing number of injections administered. Some studies
show trends of healthcare professionals themselves starting to
hesitate about vaccination [9]. This is a problem given their posi-
tion as a trusted source of vaccine information for parents and
other individuals and their influence on the level of confidence in
vaccination as a health option [10].
In 2016, a global survey in 67 countries on vaccine hesitancy
indicated that Europe was the region in the world with the least
confidence in vaccine importance, safety and effectiveness [11].
The results showed that 45% of the French population disagreed
with the statement ‘vaccines are safe’ compared with an average
of 17% in Europe, and a global average of 13%. Similarly, a system-
atic literature review found that the most common vaccine con-
cern among European populations is the fear of adverse events,
with the perceived risk varying between vaccines [7]. A recent
WHO/UNICEF assessment of vaccine hesitancy showed that hesi-
tancy was common (>90% of countries), and that lack of scientific
evidence on benefit-risk was the most frequently cited reason
[12]. The monitoring of on-line news media during a risk assess-
ment for HPV vaccines by the EU regulatory network in 2015,
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Fig. 1. Summary of vaccine introduction against more than 20 infectious diseases since 1798 up to 2016 (from WHO [3]).
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revealed that those critical about the safety of these vaccines had a
wide range of questions on safety issues [13]. The decline in HPV
vaccine uptake following safety scares in Denmark, the decline in
influenza vaccine uptake in Germany following the 2009 pan-
demic, and the decline in MMR uptake in the UK following the
Wakefield publication, and currently numerous measles outbreaks
across Europe are some examples of the consequences of how con-
fidence and acceptance of vaccination can be undermined [14–18].
1.3. Why we need post-marketing evidence
Like with other pharmaceutical products, adverse reactions are
rare but may occur after vaccination. Because vaccines are mostly
given to healthy persons and in large numbers, rapid benefit-risk
monitoring is very essential. The background incidence rates of
some serious adverse events suspected to be associated with vac-
cines are very low, e.g. Guillain-Barré Syndrome (2/100,000
person-years) and narcolepsy (1/100,000 person-years). Pre-
licensure efficacy and safety clinical trials, that can detect more
frequent events such as fever, are not sized to detect events with
a frequency of <1/10,000 person-years [19,20]. As a result, contin-
uous post-marketing monitoring of vaccine safety is needed to
identify and evaluate potentially rare adverse events and to enable
re-assessment of vaccine benefit-risk. Spontaneous reporting of
adverse events is still the cornerstone of most post-marketing
safety monitoring systems, but with the increasing availability of
electronic healthcare data, new options for safety surveillance have
become available [21–23]. The potential of these large, linked data
sources for vaccine safety monitoring was first recognised in the
USA in 1990, with the establishment of a collaboration between
the US Centres for Disease Control and Prevention and eight health
maintenance organisations to create the Vaccine Safety Datalink
(VSD) [24,25].
2. Why we need to collaborate
The added-value of vaccine benefit-risk monitoring across indi-
vidual healthcare plans or provinces was recognised and publicly-
funded in North America (US: VSD in 1990 Sentinel in 2010 and the
Innovation in Medical Evidence Development an Surveillance
(IMEDS) program), Canada: Canadian Immunisation Research Net-
work (CIRN) in 2009) [26–28]. In contrast, in Europe, most of the
monitoring of vaccine coverage, benefit and risk is done nationally,
and long-term public funding for a system to collaborate to moni-
tor vaccine benefits and risks on a European level is not available
currently [29].
During the 2009 influenza pandemic, several new vaccines were
licensed and used in large populations. This demonstrated the need
for collaboration at many levels and highlighted how post-
marketing monitoring systems in the EU could be improved by
developing amongst others [30] increased and transparent interac-
tions between public and private stakeholders, better communica-
tion on the respective roles and responsibilities of the various
European bodies and agencies (i.e., European Commission (EC),
EMA and European Centre for Disease Prevention and Control
(ECDC)), common approaches to studies for readiness to respond
and better communication strategies to share new data promptly
and transparently.
Collaboration and sharing of data should increase the capacity to
quantify risks and benefits, allow comparisons between product
brands and vaccination schedules, and promote knowledge sharing.
The need for collaboration to generate evidence for benefits-risk
monitoring was recognised and presented to the Innovative
Medicines Initiative (IMI) by the vaccine manufacturers. IMI is an
initiative jointly-funded by the EC and the European Federation
of Pharmaceutical Industries and Associations (EFPIA). IMI issued
a call for proposals for a public-private partnership to build and
test methods for components of a collaborative, distributed system
for benefit-risk monitoring of vaccines and, as a result, they funded
the ADVANCE (Accelerated development of vaccine benefit-risk
collaboration in Europe) project.
The ADVANCE project was built on the premise that an inte-
grated, sustainable, continuous vaccine monitoring system is of
paramount importance for obtaining up-to-date, accessible infor-
mation on the coverage, benefits, risks and impact of vaccines.
Readily accessible information might help to build and maintain
public trust in vaccines and facilitate informed decision-making
for the regulation of vaccines, immunisation policies and vaccina-
tion of individuals. ADVANCE focuses on the secondary use of
available, existing EU healthcare data, which could provide real-
world evidence on vaccine benefit-risk to inform on the best use
of vaccines. Social media data are used to listen to the public prior
to communication [13]. The ADVANCE consortium comprises key
public and private vaccine stakeholders in Europe including the
ECDC and EMA, with 47 full and associate partners in multiple
domains (16 academic/public research institutions, 3 small med-
ium enterprises (SMEs), 2 charities, 10 public health organisations,
9 medicines regulatory authorities, 7 vaccine manufacturers) (see
Appendix and Fig. 2).
3. The needs of different European vaccine stakeholders
A needs assessment was conducted within the ADVANCE pro-
ject as well as during a face-to-face broader stakeholder forum that
was organised by the EMA at the beginning of the project. The var-
ious stakeholders have some common, shared, multiple needs. The
identified common needs include up-to-date, valid and easily
accessible information for decision-making, detailed characteriza-
tion of available electronic healthcare data (EHR) sources, validated
methods to assess vaccination coverage, benefits and risks from
available EHR databases, transparency about the roles, responsibil-
ities and contributions of all stakeholders and effective communi-
cation methods to address public concerns.
The challenges for generating such information across EU mem-
ber states are numerous, including the various coding systems and
language used in the different data sources and the diverse imple-
mentation of European directives and regulations regarding re-use
of health data. Stakeholders with specific EU-wide responsibilities
for vaccine coverage, benefit and risk monitoring face also many
challenges when using real-world data from electronic healthcare
databases. These challenges include trust in the quality of the data
and the interpretation, the speed at which evidence can be made
available and the methods for pooling evidence, which all require
close attention, particularly when evidence is combined from sev-
eral sources [31].
To provide insight into the background of specific needs we
describe the perspectives of the regulatory authorities, public
health institutes and vaccine manufacturers, each of which may
need to consider an EU perspective when making decisions on
licensing, vaccine programmes and risk management.
3.1. Regulatory agency perspective
The EU medicines regulatory network is responsible for the pro-
tection of the public by authorising safe and effective vaccines and
by continuously monitoring their post-marketing benefits and
risks [32]. Spontaneous reporting of suspected adverse reactions
by healthcare professionals and the public is at the core of this
post-marketing monitoring. From 2012 to 2017, 175,184 reports
(5.5% of all reports) to EudraVigilance reviewed by a national
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regulatory agency in an EUmember state or the EMAwere vaccine-
related individual case reports. Confirmed signals of potential
safety issues detected through this system undergo rigorous scien-
tific evaluation of all available evidence [33]. Real-world evidence
on the use, benefits and risks of vaccines during the entire life-
cycle of the vaccine is needed to assess these signals. To assess
safety signals quickly, regulatory authorities and vaccine manufac-
turers compare observed versus expected numbers of cases of
adverse events [34]. This analysis requires near-real-time exposure
data, appropriately stratified background incidence rates of specific
adverse events (to calculate the expected number of cases) and
sensitivity analyses around these measures. However these
observed/expected analyses are frequently affected by uncertain-
ties regarding the numbers of vaccinated individuals and age-
specific background incidence rates [35]. The availability of such
population data and quick access to it are often issues, particularly
in situations where regulatory authorities need evidence quickly,
as in the case of rapid employment of mass vaccination [36].
Regulator authorities can require vaccine manufacturers to con-
duct a post-authorisation safety study (PASS) to investigate a safety
concern, or to agree with the company that a PASS will be included
in the product’s risk management plan. Secondary use of routinely-
collected data in electronic healthcare databases is frequent in such
studies because these data are already available for transformation
into evidence, thus making evidence available faster than collecting
primary data, especially if a large study population is needed. The
framework developed by ADVANCE may, therefore, become an
essential component of vaccine benefit-risk monitoring for
regulators by enabling access to and supporting the analysis of an
extensive range ofmulti-national real-world data from various data
sources to create and monitor evidence on vaccine coverage,
benefits and risks, which may facilitate regulatory decision-
making during the entire product life-cycle. Use of relevant
sources of information for the EU regulatory network could be
supported by the ADVANCE system if it would provide access to
well characterized EHR datasources, use of validated and transpar-
ent methods, use best epidemiological practices, have robust
governance, clear communication practices and be sustainable.
3.2. Public health institution perspective
PHIs are key organisations responsible for epidemiological
surveillance and control of vaccine-preventable diseases, and for
providing advice and guidance about the use of vaccines in
national immunisation programmes. Access to larger sample sizes
than in national or sub-national primary data collection and
surveillance studies and the ability to compare the impact of differ-
ent vaccination schedules and recommendations are some exam-
ples of the added-value of using the available EHR data sources
in Europe for evidence generation. During the early phases of the
ADVANCE project, participating PHIs defined the following success
measures, reflecting their needs and perspectives: faster, reliable,
integrated and harmonized analyses on coverage, benefits, risks
and benefit-risk in Europe validated through peer-reviewed publi-
cations, sustainable and allowing for capacity building in less
active countries.
3.3. Vaccine manufacturer (marketing authorisation holders)
perspective
Vaccine marketing authorisation holders (MAHs) have legal
obligations to monitor the benefits, safety and benefit-risk profiles
of their licensed vaccines, throughout their life cycle. As the vac-
cine moves from the pre-marketing to post-marketing period and
as years of experience with its use accrue, the types of activities
required evolve. During early vaccine development, MAHs can con-
duct studies to understand the background epidemiology of the
disease in the targeted population. They can also estimate the
expected background incidence rates of some anticipated adverse
events to be able to evaluate if the rates of these events observed
Fig. 2. Distribution of ADVANCE partners.
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during the clinical programme and, ultimately in the post-
marketing period, exceed the expected rates. MAHs are obliged
to monitor the safety of their products during the post-marketing
period and submit reports of suspected adverse reactions concern-
ing their products licensed in Europe to EudraVigilance. Additional
studies, beyond regular resources (e.g., the placebo group from a
trial, surveillance of benefits, spontaneous reporting of suspected
adverse reactions) may be necessary in case of concerns at or after
licensing. These may be voluntary or required and may be con-
ducted to study potential risks and effectiveness of the products
as part of the pharmacovigilance risk management plan that is
approved by the EMA at licensure and is periodically updated dur-
ing the product life cycle. The feasibility of these studies is directly
dependent on the availability of data and access to persons who
can transform these data into the required evidence in a timely
manner. The expectations of MAHs are that, with the quality-
assured and tested ADVANCE system, companies will more easily
be able to use data and experts to provide evidence, which would
otherwise not be accessible. The ultimate goal is to ensure timely
provision of evidence on brand-specific vaccine coverage and util-
isation data, background incidence rates of events of interest to
support evaluations of safety issues, and if needed national or
multi-country vaccine effectiveness and safety studies.
4. Conclusions and future perspective
Based on the lessons learned from the 2009 influenza pandemic,
the needs expressed by stakeholders and their common goal to
improve the continuous and rapid monitoring of the benefits and
risks of vaccines, the ADVANCE project has brought together Euro-
pean vaccine stakeholders to design, implement and evaluate the
environment, workflows and systems to generate actionable evi-
dence on vaccine coverage, benefits and risks within our public-
private collaborative framework. All stakeholders share needs for
valid evidence and they can provide unique expertise and play
an important role in the process of evidence generation. This is
key for all drugs, but vaccines are special as they are targeted for
primary prevention to large, healthy populations. Although evi-
dence on benefits and risks is not, by itself, enough to build trust
when safety concerns arise, the absence of evidence and answers
may generate mistrust, and lack of scientific evidence on benefits
and risks was listed most frequently as a reasons for hesitancy in
the WHO/UNICEF investigation [12]. The rapid availability of such
evidence will therefore ultimately serve society as a whole.
To date, the ADVANCE consortium has addressed a number of
the stakeholders’ expressed needs and delivered tools, methods
and best practice guidance [37,38] (www.advance-vaccines.eu),
specific for vaccine benefit-risk monitoring. The papers in this sup-
plement describe the ADVANCE system components for evidence
generation from real world health data and their evaluation in
proof of concept studies.
Many of the solutions developed in the ADVANCE project can be
applied to benefit-risk monitoring of therapeutics, and several
solutions in ADVANCE were taken from systems set up for drug
related studies in the past. ADVANCE wanted to build a separate
ecosystem for vaccines since the vaccine area is more complex
than the therapeutic area, for example national public health insti-
tutes are important experts and stakeholders, and data on vaccines
are often kept in separate registries. The ADVANCE system, meth-
ods and tools will be implemented in the VAccine monitoring Col-
laboration for Europe (VAC4EU) after the project and funding
ended in March 2019. VAC4EU (www.vac4eu.org) is a non-for
profit organization that unites the stakeholders in a different gov-
ernance structure. This legal entity is open to new partners
(research organizations and public health institutes) and aims to
collaborate with other initiatives such as VSD, PRISM, IMEDS as
well as the Global Vaccine data Network or initiatives that focus
on primary data collection, to rapidly monitor vaccine benefits
and risks across continents.
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Appendix A. Organisations and persons actively involved in the
ADVANCE consortium
ADVANCE Full partners
AEMPS: Agencia Española de Medicamentos y Productos Sani-
tarios (www.aemps.es)
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ARS-Toscana: Agenzia regionale di sanità della Toscana (https://
www.ars.toscana.it/it/)
ASLCR: Azienda Sanitaria Locale della Provincia di Cremona
(www.aslcremona.it)
AUH: Aarhus Universitetshospital (kea.au.dk/en/home)
ECDC: European Centre of Disease Prevention and Control
(www.ecdc.europa.eu)
EMA: European Medicines Agency (www.ema.europa.eu)
EMC: Erasmus Universitair Medisch Centrum Rotterdam (www.
erasmusmc.nl)
GSK: GlaxoSmithKline Biologicals (www.gsk.com)
IDIAP: Jordi Gol Fundació Institut Universitari per a la Recerca a
l’Atenció Primària de Salut Jordi Gol i Gurina (http://www.
idiapjordigol.com)
JANSSEN: Janssen Vaccines - Prevention B.V. (http://www.jans-
sen.com/infectious-diseases-and-vaccines/crucell)
KI: Karolinska Institutet (ki.se/meb)
LSHTM: London School of Hygiene & Tropical Medicine (www.
lshtm.ac.uk)
MHRA: Medicines and Healthcare products Regulatory Agency
(www.mhra.gov.uk/)
MSD: Merck Sharp & Dohme Corp. (www.merck.com)
NOVARTIS: Novartis Pharma AG (www.novartisvaccines.com)
OU: The Open University (www.open.ac.uk)
P95: P95 (www.p-95.com)
PEDIANET: Società Servizi Telematici SRL (www.pedianet.it)
PFIZER: Pfizer Limited (www.pfizer.co.uk)
RCGP: Royal College of General Practitioners (www.rcgp.org.uk)
RIVM: Rijksinstituut voor Volksgezondheid en Milieu (www.
rivm.nl)
SCIENSANO: Sciensano (https://www.sciensano.be)
SP: Sanofi Pasteur (www.sanofipasteur.com)
SSI: Statens Serum Institut (www.ssi.dk)
SURREY: The University of Surrey (www.surrey.ac.uk)
SYNAPSE: Synapse Research Management Partners, S.L. (www.
synapse-managers.com)
TAKEDA: Takeda Pharmaceuticals International GmbH (www.
tpi.takeda.com)
UNIBAS-UKBB: Universitaet Basel – Children’s Hospital Basel
(www.unibas.ch)
UTA: Tampereen Yliopisto (www.uta.fi)
ADVANCE Associate partners
AIFA: Italian Medicines Agency (www.agenziafarmaco.it)
ANSM: French National Agency for Medicines and Health Prod-
ucts Safety (ansm.sante.fr)
BCF: Brighton Collaboration Foundation (brightoncollaboration.
org)
EOF: Helenic Medicines Agency, National Organisation for
Medicines (www.eof.gr)
FISABIO: Foundation for the Promotion of Health and Biomedi-
cal Research (www.fisabio.es)
HCDCP: Hellenic Centre for Disease Control and Prevention
(www.keelpno.gr)
ICL: Imperial College London (www.imperial.ac.uk)
IMB/HPRA: Irish Medicines Board (www.hpra.ie)
IRD: Institut de Recherche et Développement (www.ird.fr)
NCE: National Center for Epidemiology (www.oek.hu)
NSPH: Hellenic National School of Public Health (www.nsph.gr)
PHE: Public Health England (www.gov.uk/government/organi-
sations/public-health-england)
THL: National Institute for Health and Welfare (www.thl.fi)
UMCU: Universitair Medisch Centrum Utrecht (www.umcu.nl)
UOA: University of Athens (www.uoa.gr)
UNIME: University of Messina (www.unime.it)
Vaccine.Grid: Vaccine.Grid (http://www.vaccinegrid.org/)
VVKT: State Medicines Control Agency (www.vvkt.lt)
WUM: Polish Medicines Agency - Warszawski Uniwersytet
Medyczny (https://wld.wum.edu.pl/)
Appendix B. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.vaccine.2019.07.081.
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